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ABSTRACT 
In Côte d’Ivoire pharmacopoeia the antifungal virtues of the bark of Terminalia mantaly are known. It bark is used to cure 
affections such as cutaneous candidiasis, gingivitis and diarrhoea. This work aims to compare the anticandidosic activities of the 
crude extract of T. mantaly and an ointment containing shea butter and the crude extract of T. mantaly. The anticandidosic activity 
of the crude Shea butter was also evaluated and kétoconazole was used as standards for antifungal assay. 
Shea butter, kétoconazole, crude extract of T. mantaly and the ointment were separately incorporated to Sabouraud agar using the 
agar slanted double dilution method. The anti-fungal tests were performed by sowing 1000 cells of Candida albicans on a 
previously prepared medium culture. Antifungal activity was determined by evaluating of anti-fungal parameters values (minimal 
fungicidal concentrations MFC and IC50). 
The results of the tests indicate that C. albicans is sensitive to each substance tested, however crude Shea butter has only 
fungistatic activity and the ointment (MFC= 1.874µg/mL) was the most active. This ointment is 52 times more active than the 
crude extract of T mantaly (MFC is of 97.5 µg/mL), 208.11 more active than kétoconazole (MFC = 390 µg/mL).  
Keywords: Terminalia mantaly, Activity, ointment  
 
 
INTRODUCTION  
In the world, the infectious diseases knew higher fresh 
outbreak during the last decades (
1
Dromer et al., 
2013).The diseases due to pathogenic resistant species 
are in great progression (
2
Assob and Nsagha, 2014) and 
mycosis are among these pathologies (
3 
Hitchkock, 
1993:  
1
Dromer et al., 2013;  
2
Assob and Nsagha, 2014). 
This fresh outbreak of mycosis comes from several 
factors. Among them, change in the clinical spectrum of 
classic pathogenic, apparition of diverse resistances in 
the usual antifungals and the strong progress of 
immunodépressive affections such as HIV-AIDS (
3 
Chabasse, 1994; 
4 
Chabasse et al., 2009; 
1
Dromer et al., 
2013). Their frequency, their recurring character and 
their gravity did not cease growing in West Africa 
generally and in Côte d'Ivoire in particular (
5
Akakpo-
Akue, 2009; 
6
Attoh-Toure et al., 2009). 
On the therapeutic level, the number of proposed 
remedies remains limited. Moreover some molecules 
lost their effectiveness due to resistance phenomena and 
change (
7
Vanden, 1997; 
8 
Sanglard et al., 1998; 
9 
Freiman and Sasseville, 2006). To this is added the cost 
more and more raised of some medicine sold in the 
modern pharmacies. The financial difficulties of the 
populations direct them to the use of healing plants 
(
10
Aké-Assi, 1991; 
11 
Cowan, 1999). The determination 
of the pharmacological properties of the healing plants 
could bring a solution to their needs (
12 
Hostettmann and 
Marston, 2002; 
2 
Assob and Nsagha, 2014), especially as 
several works have already proved the efficiency of 
molecules and extract from plants against diverse 
bacterial and fungal sorts (species) (
13 
Aladesanmi et al., 
2007; 
14 
Nkomo and Kambizi, 2009; 
15 
Kuete et al., 
2010; 
16 
Ahon et al., 2012; 
17 
Kra et al., 2015). 
Soumahoro et al                                          Journal of Drug Delivery & Therapeutics. 2016; 6(5):41-45                           42 
© 2011-16, JDDT. All Rights Reserved                            ISSN: 2250-1177                                         CODEN (USA): JDDTAO 
Furthermore, at the end of an ethnobotanic survey 
realized by our research team in 1991 in the area of Issia 
in Côte d'ivoire, T mantaly was collected and identified 
among this plants species frequently used for their anti-
infectious properties (
18 
Zirihi, 1991). In Côte 
d'ivoire,this plant is used against gastroenteritidis, oral 
affections, skin disorders, genital candidiasis, arterial 
high blood pressure and diabetes (
19 
Riviere et al., 2005, 
20 
Yayé et al., 2012). Otherwise, recent works proved 
that T. mantaly possesses excellent antibacterial and 
antifungal activities (
15 
Kueté et al., 2010; 
21-22
Yayé et 
al., 2011 et 2012; 
23 
Ackah et al., 2014; 
24 
Kra et al., 
2014). For better appreciation of the use of T mantaly in 
human therapeutics, the present study was initiated to 
evaluate and compare the anticandidosic activities of the 
crude hydroethanolic extract of T. mantaly and to those 
of the ointment formulated from this extract.  
MATERIAL AND METHODS  
Plant Material  
Bark of Terminalia mantaly  
The Plant material was a powder obtained after crushing 
the dried bark pieces of T mantaly codified TEKAM1. 
Shea Butter  
The Shea butter (SB) was extracted from nuts of 
Butyrospermum parkii (G Don) Kotschy (Sapotaceae). 
This species spontaneously grows in the north of Côte 
d'Ivoire. The SB was heated and purified by decantation. 
Microorganism Studied 
The tested fungus was the clinical and identified strain 
of C. albicans (13-298). This strain was provided by the 
Laboratory of Mycology of the Medical Sciences 
Faculty of the Felix Houphouët Boigny University 
(Abidjan, Côte d'Ivoire).  
METHODS  
Preparation of the vegetable extracts  
Extraction  
The plant bark was cut into small pieces and carefully 
air-dried for 2 weeks at room temperature in the 
laboratory, under continuous ventilation, away from 
sunlight and dust. After this step, the vegetal piece was 
crushed to a fine powder with an electric grinder IKA-
MAG. The powder obtained were codified TEKAM1. 
The hydro-ethanolic rough extracts were prepared from 
TEKAM1. Hundred grams (100g) of bark powder was 
extracted by homogenization in a blender with 1 L of 
mixture of ethanol 70% and distilled water 30%. After 
six cycles of homogenization, the homogenates obtained 
were first wrung out in a fabric square and then filtered 
twice successively with absorbent cotton and once with 
Whatman 3 mm filter paper. The resulting filtrate was 
concentrated under vacuum using a Büchi rotary 
evaporator at 60°C (
25 
Zirihi et al., 2011). This powder 
was hermetically sealed in polyethylene bags and stored 
away from light and moisture until the time of 
extraction. Dark powder obtained is the hydro-ethanolic 
crude extract codified TEKAM1-X0   
The shea butter (SB)  
SB is a clear yellow product.  It was used as excipient 
main of the ointment. It melting point is between 33 and 
42 °C. Its density at 15°C is between 0,915 and 0,920.   
Oitment Quality  
Macroscopic Characters  
The clear brown ointment obtained by the mixture of 
Shea and extract TEKAM 1- X0 codified TEPOM.  It is 
an unctuous cream with soft consistency. The smell like 
of the Shea butter    
Homogénéity  
The ointment homogeneity was verified by applying on 
thin (confinement) layer a plane surface using a spatula.  
The regular distribution or not of the extracts in 
excipient was noted. It presents a very homogeneous 
without curds and smooth aspect to the touch. 
pH Measure 
The pH determined was that of a dilution to the tenth of 
the ointment in heater distilled water. The pH obtained 
is generally 5, 5. 
Medium and ointment preparation  
The anti-fungal tests were carried out on culture medium 
Sabouraud (Biomerieux / Ref: 180930; batch 401513b). 
The incorporation of plant extracts into the agar was 
made using the agar slanted double dilution method (
26 
Ajello et al., 1963; 
27 
Holt, 1975; 
28
 Zirihi et al., 2003).  
For each substance as TEKAM1, SB, and the ointment, 
serial tests were realized and each serie include 12 tests 
tubes. Ten test tubes contain mixture of vegetable 
extract and agar. The others 2 tubes constitute the pilot. 
Among these two tubes, one without vegetable extract 
was considered as witness of germs growth control 
while the second without germs and extract was 
constitute witness of culture medium sterility control 
growth. Extract concentrations range in the tubes from 
2500µg/mL to 0,003µg/mL with geometrical connection 
of reason ½. All the tubes were pressure-sealed at 121°C 
during 15 min, and then tilted with small base at room 
temperature to allow their cooling and solidification of 
the agar (
29
Ackah, 2004; 
30
Teas, 2008; 
31
Kporou, 2009; 
22
Yayé, et al., 2011; 
32
Ouattara et al., 2013).  
To obtain the ointment codified TEPOM, 48g of Shea 
butter were added by small fractions to 2g of TEKAM1-
X0 and mixed until obtaining complete homogeneity 
(
33
Raoult, 1983; 
34
Mathieu and Fonteneau, 2008;
35
 
Klusiewicz, 2008; 
36
Charpentier 2008; 
37
Mautrait and 
Raoult, 2009). Dimethylsulfoxide (DMSO with 1%) was 
used to facilitate the homogenization of both substances 
(
38
Boutet, 1967; 
39
Bean et al., 1969). 
Anti-microbial test 
Fungal germs culture on slanted agar previously 
prepared was made by sowing 1000 cells of C. albicans 
(
28
Holt, 1975). These cultures were incubated at 30°C 
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for 48 h. At the end of the incubation time, colonies 
were counted out by direct counting with a colony 
counter pen (Ceinceware, number 23382). The growth 
in the 10 experimental tubes was expressed as survival 
percentage, calculated, compared to 100% of growth in 
the growth control tube. The formula to calculate this is 
shown below. 
The processing of these data permitted to calculate the 
MFC values. (
26
Ajello et al., 1963; 
28
Holt, 1975) In 
practice, the MFC is the extract concentration in the 
tube, which gave 99.99% inhibition compared to the 
control growth tube It also made possible to plot the 
curves of activity of the extracts and the graphically 
determination of the IC50 values. 
Formula to calculate the survival percentage: 
 
 
 
S: Survival (%) 
n: Number of colony in one experimental tube 
N: Number of colony in the growth control tube. 
RESULTS  
After 48 hours of incubation at 30ºC, we observed 
comparatively to control tube a progressive decrease in 
the number of colonies gradually as the concentrations 
of the plant extract increased in the experimental tubes. 
The results were summarized in the form of curves of 
activity on Figure 1 and in table I containing the various 
values of MFC and IC50. 
In general, all sensitivity curves showed a progressively 
decreasing pace with slopes that are stronger or not as 
strong according to the extracts. The TEPOM 
accentuated slope curve illustrates high anti-fungal 
potency. In contrast the Shea slope curve is less 
accentuated. It reveals low anti-fungal potency of this 
SB.
 
 
Figure 1: Sensitivity of Candida albicans to TEKAM1-X0, SB, TPOM and Kétoconazole 
 
Table I: Values of anti-fungal parameters of TEPOM, 
TEKAM1- X0   and Kétoconazole 
Tested 
Substances  
Antifungal parameters (µg/mL) 
CI50 CMF 
TEKAM1-X0 1,14 97,5 
TEPOM 0,047 1,874 
SB 417,85 Non enregistré  
Kétoconazole 18,455 390 
 
DISCUSSION  
The analysis of the whole results shows that C. albicans 
is sensitive to all substances tested namely TEKAM1-
X0, SB, TEPOM and Kétoconazole according to relation 
dosis-dependent. However, the levels of these anti-fungal 
activities are variable from one substance to another. 
According to the classification scale of the levels of the 
activities of 
24
Kra et al.,(2014), TEPOM, TEKAM1-X0 
and Kétoconazole anti-fungal activities are classified as 
very high levels of activity. The anticandidosic activity 
of SB is very low. Among these substances, TEPOM is 
most active on C. albicans for having generated the 
lowest values of MFC (1.874µg/mL) and IC50 
(0.047µg/mL). In contrast, of TEPOM, SB was the less 
active. It generated a fungistatic activity because none 
tested concentration completely inhibited the growth of 
C albicans. On picture 1, its activity curve slope is very 
weak. The activities of TEKAM1-X0 (MFC=97.5µg/mL 
and IC 50 = 1.14µg/mL) and Kétoconazole (MFC = 
390µg/mL and IC 50 = 18.455µg/mL) range between 
these two extremes. 
On the basis of CMF and IC50 values, the comparison 
reveals that TEKAM1-X0 is 4 times more active than 
Kétoconazole and 366.53 times more active than SB. 
Moreover, TEPOM is 52.02 times more active than 
TEKAM1-X0, 208.64times more active than 
Kétoconazole and 8890.42 times more active than SB. 
So, incorporation of TEKAM1-X0 extract in the Shea 
butter has generated a strong increase in the antifungal 
activity of this crude extract. This activity was multiplied 
by 52.02. The SB has noticeably maximized 
anticandidosic activity of TEKAM1-X0. This TEPOM 
can be a cure against skin mycosis. A similar product has 
0 
25 
50 
75 
100 
0 97.5 195 292.5 390 
Su
rv
iv
al
 o
f 
 C
. a
lb
ic
an
s 
(%
) 
 concentration (µg/mL)        
Pommade 
TEKAM1-Xo 
BK 
Ketoconazole 
S = 
N
n
 
x 100 
Soumahoro et al                                          Journal of Drug Delivery & Therapeutics. 2016; 6(5):41-45                           44 
© 2011-16, JDDT. All Rights Reserved                            ISSN: 2250-1177                                         CODEN (USA): JDDTAO 
already been formulated by 
6
Akakpo -Akué et al. (2009). 
These authors developed an antifungal cream using 
hydroethanolic extract of T. catappa and a neutral cream. 
This codified cream DAEL exhibited an excellent 
antifungal activity against C. albicans (MFC =3μg/mL) 
and T mentagrophytes (MFC = 2.4μg/mL). This DAEL 
cream was also used to cure diverse dermatosis such as 
the cropping trichophytic moths, the croppings 
microsporic moths, the intertrigo interdigito-plantar, the 
dermatophytie of the skin glabrous, the pityriasis 
versicolor. However, the comparison of the 
anticandidosic activities of TEPOM with that of DAEL 
antifungal cream (MFC=3µg/mL) reveals that TEPOM is 
1.6 times more active than DAEL cream. 
On the other hand, the qualities of the obtained ointment 
are similar to those obtained by 
40
Rokia et al.,(2006) by 
its consistence, its pH (5.5) and its perfect homogeneity. 
However, the very strong anticandidosic activity of 
TEKAM1-X0 has already been reported by
24-18
 Kra et 
al., (2014 and 2015) and 
21
Yayé et al., (2012) who 
worked in similar conditions with T mantaly barks. 
However the comparison of extract’s performances 
reveals that TEKAM1-X0 from the present study is 
respectively 2 times and 21.92 times more active than the 
extracts prepared by these authors. 
The differences of performances of these extracts could 
be explained by the fact that we did not collect the barks 
in the same area, and we did not test the extracts on the 
same C. albicans strain. And each fungal strain has its 
own sensitivity to anti-fungal drugs. 
Works of 
41
Baba-moussa et al. (1999) also showed that 
extracts from Terminalia avicennioides produced a 
strong antifungal activity against C albicans. But the 
comparison reveals that TEKAM1-X0 (MFC = 97.5 μ G 
/ ml) is 2.54 to 41 times more active than the extracts 
obtained by these authors. TEKAM1-X0 is also 31,2 
times more active than MISCA-X1.1 (CMF=3.125 
mg/mL) prepared from Mitracarpus villosus by 
31
Kporou 
et al., (2009).On the other hand TEKAM1-X0 is 8 to 128 
times more active than methanolic and ethanolic extracts 
of the leaves and the fruits of Rubus sanguineus tested by 
42
Zeidan et al (2013) on C albicans. In addition, the 
dichloromethane extracts of Olea cuspidate and Olea 
glandulifera are 256.41 to 512.82 times less active than 
TEKAM1-X0 because they produced antifungal 
activities with values going from 25 mg/ml to 50 Mg / 
mL on C albicans (
43
Majgaine and Verma, 2013). 
TEKAM1-X0 is respectively 16 times and 69 times less 
active than the hydroalcoholic extracts T3-X12 of 
Terminalia catappa tested by 
44
Ackah et al.,(2008) on C. 
albicans . 
Concerning SB, its anti-fungal activity is certainly due to 
the fact that it contains 3 to 17 % of insaponifiables 
which are the karitenes A, B, C and D, the β-amyrine, 
basseol, the butyrospermol, the parkeol, the luseol; 
Karistérols A and B and vitamins A and D which give 
her bacteriostatic antioxidant and fungistatic properties. 
The results of the present study confirm the very high 
antimicrobial potency extracts from plants in the 
Terminalia genus. Moreover results of many previous 
studies are in agreements with this study concerning their 
strong antimicrobial activities. 
CONCLUSION  
The present study focuses on the anti-infectious potency 
of Terminalia mantaly.  The results of these experiences 
show that sensitivity of C. albicans is dose-response 
relationship. The extract effectiveness is more important 
when it is incorporated in ointment than used alone. 
TEPOM activity being 52 higher times than isolated 
crude extract, then SB noticeably increased 
anticandidosic extract activity. Furthermore TEPOM 
being much more active than the kétoconazole, this 
ointment can be a cure against skin mycosis. Finally 
from the present study it appears that using Terminalia 
mantaly as antimicrobial in rural area is justified. 
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